Abstracts Archive - Page 164 of 2607 - ACR Meeting Abstracts

Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Areeka Memon¹, Monique Hinchcliff² and Amir Masoud³, ¹Yale New Haven Health, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Hartford Healthcare, hartford
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
Abstract Number: 0696 • ACR Convergence 2025
Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis
Jeska de Vries-Bouwstra¹, Jingjing He², Xu Wang², Saad Ahmed², Jeroen J. Bax² and Nina Ajmone Marsan², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Myocardial involvement in systemic sclerosis (SSc) represents a severe complication with a poor prognosis; however, compromised cardiac function also heightens the risk of life-threatening…
Abstract Number: 0610 • ACR Convergence 2025
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
Emma Trachman¹, Amanda Eudy² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…
Abstract Number: 0702 • ACR Convergence 2025
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Nicola Farina¹, Silvia Bellando-Randone², hilde Bjørkekjær³, David Launay⁴, Patricia E. Carreira⁵, paolo airò⁶, Serena Guiducci⁷, Dilia Giuggioli⁸, Gabriela Riemekasten⁹, carmen-Pilar Simeón Aznar¹⁰, Christina Bergmann¹¹, Elise Siegert¹², Ivan Castellví¹³, Lesley Ann Saketkoo¹⁴, Jeska de Vries-Bouwstra¹⁵, Dr. Philipp Klemm¹⁶, ulf Müller-Ladner¹⁷, Alexandra Balbir- Gurman¹⁸, Vanessa Smith¹⁹, Florenzo Iannone²⁰, Luca Idolazzi²¹, Christopher Denton²², edoardo rosato²³, Britta Maurer²⁴, Yannick Allanore²⁵, Yoshiya Tanaka²⁶, elisabetta zanatta²⁷, Marie-Elise Truchetet²⁸, Masataka Kuwana²⁹, Mickaël MARTIN³⁰, Alberto Cauli³¹, Kamal Solanki³², Francesco Del Galdo³³, Ana Maria Gheorghiu³⁴, Branimir Anic³⁵, Gábor Kumánovics³⁶, Gonçalo Boleto³⁷, Kristofer Andréasson³⁸, Simona Rednic³⁹, Lorinda Chung⁴⁰, susana Oliveira⁴¹, marius cadar⁴², Francesco Paolo Cantatore⁴³, Carolina de Souza Müller⁴⁴, Vivien Hsu⁴⁵, Yair Levy⁴⁶, Gianluca Moroncini⁴⁷, Jörg Henes⁴⁸, Andra Balanescu⁴⁹, and Ellen De Langhe⁵⁰, , Carlomaurizio Montecucco⁵¹, Petros Sfikakis⁵², Michele Iudici⁵³, Stefan Heitmann⁵⁴, Madelon Vonk⁵⁵, Anna-Maria Hoffmann-Vold⁵⁶, Oliver Distler⁵⁷, Marco Matucci-Cen⁵⁸, Cosimo Bruni⁵⁷, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁷Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁰Hospital Universitario Vall d'Hebron Passeig, Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Barcelona, Spain, Zaragoza, Spain, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹²Charité University Hospital, Department of Rheumatology, Berlin, Germany, Berlin, Germany, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Kerckhoff-Klinik Bad Nauheim, Berlin, Germany, ¹⁷JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹⁸Rambam Health Care Campus, Rheumatology Institute, Haifa, Israel, israel, Israel, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ²¹Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ²²University College London, UK, London, United Kingdom, ²³Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policlinico Umberto ¹-Centro di riferimento regionale per la sclerosi sistemica, Rome, Italy, rome, Italy, ²⁴Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²⁵Université Paris Cité, Paris, France, ²⁶University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²⁷Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ²⁸Bordeaux University Hospital, Bordeaux, France, ²⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³⁰Poitiers University Hospital, Department of Internal Medicine, Poitiers, France, MIGNALOUX-BEAUVOIR, France, ³¹Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, ³²Waikato Hospital, Hamilton, New Zealand, ³³University of Leeds, Leeds, United Kingdom, ³⁴Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ³⁵University of Zagreb, School of Medicine, University Hospital Center Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, zagreb, Croatia, ³⁶University of Pécs, Department Of Rheumatology And Immunology, Medical Centre, Pecs, Hungary, Pecs, Hungary, ³⁷Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal, Paris, France, ³⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ³⁹University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Clinica Reumatologie, Cluj-Napoca, Romania, Cluj-Napoca, Romania, ⁴⁰Stanford University, Stanford, CA, ⁴¹Fernando Fonseca Hospital, Department of Medicine IV, Systemic Immunomediated Diseases Unit, Amadora, Portugal, amadora, Portugal, ⁴²Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Rome, Italy, ⁴³University of Foggia, Department of Medical and Surgical Sciences, Rheumatology Unit, Foggia, Italy, foggia, Italy, ⁴⁴Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil, curitiba, Brazil, ⁴⁵Rutgers- RWJ Medical School, South Plainfield, NJ, ⁴⁶Meir Medical Center, Kfar-Saba, Israel, Kefar Sava, Israel, ⁴⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁴⁸Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁴⁹UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁵⁰University Hospital Leuven, Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ⁵¹Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy, ⁵²NKUA - SCHOOL OF MEDICIN, Athens, Greece, ⁵³Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵⁴Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199 Stuttgart, Germany, ⁵⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵⁶Oslo University Hospital, Oslo, Norway, ⁵⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵⁸University San Raffaele Milano, Milano, Italy

Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…
Abstract Number: 0706 • ACR Convergence 2025
Major salivary glands Ultrasound features in a group of patients with systemic sclerosis: a multicentric study
Roberto D'Alessandro¹, Francois Zimmermann², sandrine jousse³, AURORE BLEUZEN⁴, Guillaume Coiffier⁵, Jérôme Avouac⁶, Alain Lescoat⁷ and Yannick Allanore⁸, ¹Rheumatology Unit, Cochin Hospital, Paris, France, Paris, France, ²Internal medicine department, University Hospital of Rennes, Rennes, France, Rennes, France, ³LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ⁴Medical Imaging, University Hospital of Tours, Tours, France, Tours, France, ⁵Dinan Hospital, Dinan, France, ⁶Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁷CHU Rennes University Hospital, Rennes, France, ⁸Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France
Background/Purpose: Ultrasound (US) abnormalities of major salivary glands are frequent in systemic sclerosis (SSc) patients. However, US role is not yet fully understood, and the…
Abstract Number: 0645 • ACR Convergence 2025
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Eric Morand¹, Lucy Carter², Maria Dall'Era³, Michelle Petri⁴, Ed Vital⁵, Teri Jimenez⁶, Janine Gaiha-Rohrbach⁷, Bernard Lauwerys⁸, Annette Nelde⁹, Christian Stach¹⁰ and Ronald van Vollenhoven¹¹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Division of Rheumatology, University of California, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶UCB, Raleigh, NC, ⁷Biogen, Cambridge, MA, ⁸Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ⁹Biogen, Baar, Switzerland, ¹⁰UCB, Monheim am Rhein, Germany, ¹¹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects on SLE immunopathology;1,2 it consists of a polyethylene glycol (PEG)-conjugated antigen-binding fragment…
Abstract Number: 0719 • ACR Convergence 2025
A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin⁴, Stacy Ardoin¹ and Salem Almaani³, ¹Nationwide Children's Hospital, Columbus, OH, ²The Feinstein Institutes for Medical Research, Manhasset, ³OSU, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: ANCA-associated vasculitis frequently involves the kidneys causing glomerulonephritis (AAGN). Despite advances in treatment, many patients develop end-stage kidney disease. An improved understanding of the…
Abstract Number: 0700 • ACR Convergence 2025
Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
Martina Iacubino¹, Lorenzo Rocco², Marco Vicenzi², Chiara Bellocchi², Marta Mozzo³, adriana severino³, Monica Caronni³, Alessandro Santaniello³, Gaia montanelli³, Barbara Vigone³, LIam Grimmett⁴, Matt Kerr⁴ and Lorenzo Beretta⁵, ¹UNIMI, Milano, Milan, Italy, ²University of Milan, Milan, Italy, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁴Owlstone Medical, Cambridge, United Kingdom, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Accurate and early diagnosis of SSc-PAH…
Abstract Number: 0707 • ACR Convergence 2025
When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?
Samiha Karim¹, Gaobin Bao¹, Charmayne Dunlop-Thomas¹ and S. Sam Lim², ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: People from underrepresented groups with SLE can face barriers to health care and management, including discrimination and a lack of resources and social and…
Abstract Number: 0716 • ACR Convergence 2025
Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis
Chelsea Cheng¹, Justine Lafleur-Careau², Navneet Kang¹, Medha Soowamber³ and Christian Pagnoux³, ¹Mount Sinai Hospital, Toronto, Canada, ²Mount Sinai Hospital, Saint-Augustin-de-Desmaures, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem disorder characterized by asthma, rhinitis, peripheral blood eosinophilia, and necrotizing vasculitis of small vessels. Cardiac…
Abstract Number: 0598 • ACR Convergence 2025
Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
Jaspreet Bhatti¹, Kyu-In Lee², Nirali Sanghavi³, Stephen Zak⁴, Julia Ash⁵, James Miceli⁶, Kirk Sperber⁴, Stephen Pan⁷ and Amy Wasserman⁸, ¹Westchester Medical Center, Hopewell Junction, NY, ²Westchester Medical Center, Fort Lee, NJ, ³Westchester Medical Center, White Plains, NY, ⁴New York Medical College, Valhalla, ⁵Westchester Medical center, Dobbs Ferry, NY, ⁶Westchester Medical Center, Hawthorne, NY, ⁷Westchester Medical Center, Valhalla, ⁸New York Medical College at Westchester Medical Center, Armonk, NY
Background/Purpose: HCQ induced cardiomyopathy leading to heart failure is a rare but serious potential treatment complication. Currently there are no screening guidelines for detecting HCQ…
Abstract Number: 0652 • ACR Convergence 2025
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Brandon Jackson¹, Saira Sheikh², Roberto Caricchio³, Taylor Irons⁴, Maria Dall'Era⁵, Amit Saxena⁶, Alfred Kim⁷, Jose Rubio⁸, Sasha Bernatsky⁹, David Goddard¹⁰, Fotios Koumpouras¹¹, Aimee Williams¹², Maya Merrell¹³, Jennifer Meriwether¹⁴ and Stacie Bell¹⁵, ¹Lupus Therapeutics, Miami, FL, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Lupus Therapeutics, Houston, TX, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰NYU Langone Grossman SOM, Brooklyn, NY, ¹¹Yale School of Medicine, New Haven, CT, ¹²Lupus Therapeutics, Raleigh, NC, ¹³Lupus Therapeutics, Charleston, SC, ¹⁴Lupus Therapeutics, Westminster, CO, ¹⁵Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy…
Abstract Number: 0712 • ACR Convergence 2025
Effects of Bacterial Secretome on Nasal Epithelial Cell Gene Expression in ANCA-Associated Vasculitis
A. Nikolai von Krusenstiern¹, Eleni Bouziani², Sokratis Apostolidis², Li Hui Tan², Swetha Rajagopal³, Nicholas Bolden², Paul J. Planet³, Dylan Curry³, Elliot Friedman³, Noam A. Cohen⁴ and Rennie Rhee², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: The nasal microbiome has been implicated as a contributor to relapse in ANCA-associated vasculitis (AAV). Previous research on nasal bacteria, particularly Staphylococcus aureus, has…
Abstract Number: 0714 • ACR Convergence 2025
Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
Alvaro Oyarce-Calderón¹, Allison Figueroa-Sánchez², Leonor León-Yaurimucha², Rocío Gamboa-Cárdenas³, Zoila Rodríguez-Bellido⁴, Risto Perich-Campos⁵, Graciela Alarcón⁶, Manuel Ugarte-Gil⁷ and Victor Pimentel-Quiroz⁸, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁶The University of Alabama at Birmingham, Oakland, CA, ⁷Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁸Universidad Científica del Sur, San Isidro, Peru
Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and…
Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Luis Daniel Fajardo Hermosillo and María Karina Lizbeth López Ramírez, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, GUADALAJARA, Jalisco, Mexico
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].